BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ChemoCentryx, Inc. (CCXI) Announces Phase I Data With CCX507, Company's New Generation Orally Administered CCR9 Inhibitor


5/21/2013 9:25:06 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MOUNTAIN VIEW, Calif. and ORLANDO, Fla., May 21, 2013 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced data showing that CCX507, a next generation orally available inhibitor of the chemokine receptor known as CCR9, exhibited excellent pharmacokinetics and was well tolerated in a Phase I trial in healthy subjects. Preclinical data were also presented, showing that CCX507 markedly inhibited the recruitment of T cells to the intestine and significantly reduced colitis and colitis-associated wasting in inflammatory bowel disease models. The data, which were presented in a poster presentation at the Digestive Disease Week 2013 conference in Orlando, further strengthen the rationale for the use of a CCR9 antagonist in inflammatory bowel disease (IBD).

Help employers find you! Check out all the jobs and post your resume.


Read at GlobeNewswire

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES